Quick Answer
SUTRO BIOPHARMA, INC. reported Cash and Equivalents of $58.13 million for fiscal year 2025.
SUTRO BIOPHARMA, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $58.13M | -69.5% |
| 2024 | $190.30M | +174.7% |
| 2023 | $69.27M | +46.6% |
| 2022 | $47.25M | +55.4% |
| 2021 | $30.41M | -85.2% |
| 2020 | $206.15M | +4056.3% |
| 2019 | $4.96M | -96.0% |
| 2018 | $125.30M | +469.0% |
| 2017 | $22.02M | +89.9% |
| 2016 | $11.59M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $65.93M | -62.2% | +3.0% |
| June 30, 2025 | $64.03M | -29.5% | -39.7% |
| March 31, 2025 | $106.23M | +62.9% | -44.2% |
| December 31, 2024 | $190.30M | +174.7% | +9.0% |
| September 30, 2024 | $174.58M | +113.3% | +92.3% |
| June 30, 2024 | $90.79M | -61.4% | +39.2% |
| March 31, 2024 | $65.22M | +4.4% | -5.8% |
| December 31, 2023 | $69.27M | +46.6% | -15.4% |
- SUTRO BIOPHARMA, INC. showed a decrease of -69.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, SUTRO BIOPHARMA, INC.’s cash and equivalents has grown by 401.4% (from $11.59 million to $58.13 million).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: